SEMGLEE (Alphapharm Pty Ltd)
Product name
SEMGLEE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
insulin glargine
Registration type
New biosimilar medicine
Indication
SEMGLEE (solution for injection) is indicated for once-daily subcutaneous administration in the treatment of type 1 diabetes mellitus in adults and children and type 2 diabetes mellitus in adults who require insulin for the control of hyperglycaemia.